Dermatology co Foamix mulls Nasdaq IPO
Zami Aberman tells "Globes" about the pioneering work being undertaken by the placental stem cell developer.
"Among the companies I know, Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) has done the most with the least clinical data," says an expert on stem cells and investor in the life sciences.
Pluristem, which is developing placental stem cells for a range of therapies, is a pioneer in its field. The field is new and full of uncertainty. To date, the company's products have undergone a single study with 27 patients, and with no control group. Instead the results were compared with a trial by Sanofi Aventis SA (Euronext: SAN; NYSE: SNY), and most companies would take the trial with caution.
Since announcing the results of the clinical trial, Pluristem has raised $75 million from the public: $41 million in early 2011 and $34 million in September 2012. The company's market cap of $190 million is usually reserved for company's farther along in the development of their products. The company could join the Tel Aviv 100 Index, which could further boost its share price. With 104 employees, Pluristem has become one of Israel's largest biotech companies.
"This is a marvelous company in how it manages its relations with the capital market," the investor added. "Does it have a real product that works? No one can say yet."
In July and August, it seemed that every announcement by Pluristem, no matter how immaterial, sent its share price sharply higher, and it doubled during this period. The best received announcements were about successful treatments on three cancer patients in Israel under compassionate care protocols, although its leading drug candidate is for the treatment of peripheral artery disease.
This drug candidate is a placental stem cell (PLX cell) for the regrowth of blood vessels, which is indicated for the treatment of three kinds of blockage of blood vessels in the limbs. The trial included 27 patients with critical limb ischemia (CLI). The company has begun recruiting 150 patients for a Phase II clinical trial of the therapy for intermittent claudication (IC), which is due to be completed by the end of 2014. The company is also due to begin a Phase II clinical trial for the treatment of Buergers Disease (progressive inflammation and thrombosis of small and medium arteries)
"Globes": If you were analysts, how would you build a pricing model for Pluristem?
Pluristem chairman CEO Zami Aberman: "Most analysts only assess the company's late-stage products. On the basis of our leading product's potential, they reach much higher prices than our current value, and they stop there. If you add just one more of our products to the pricing, the price would be so high as to seem unreasonable."
However, this potential should be based on probabilities, i.e. the chances of success in clinical trials, market adoption of the product, and a price that creates profits for the company. These probabilities are very hard to estimate, especially for a company like Pluristem.
You obtained approval for an advanced study for critical limb ischemia 18 months ago. Why the delay?
"The US Food and Drug Administration (FDA) demanded that we first build the plant for commercial production of the stem cells, and to use exactly these cells in the trial. Our subcontractor, Biopharmax Ltd., is due to finish the plant this year, so we'll be able to begin the three-year trial in 2013."
Pluristem CFO Yaki Yanai estimates the cost of the CLI clinical trial at $15-18 million, and the cost of the IC trial at $7 million.
Will doctors help to prescribe such an innovative therapy?
Aberman: "It's a question of how simple and cheap the product is. We're producing a product that is locally administered by injection to the muscle. Current treatment is exercise and massages. For many patients, amputation is the only option."
Is there a chance that one day, you'll announce that the product doesn’t work, as happened to Pharmos?
"Since the products are different from each other, and since they all succeeded in animal studies, I don’t believe that the success is coincidental. That is why I believe that the chances of failure in all the studies are negligible."
Pluristem also has the support of United Therapeutics Corporation (Nasdaq: UTHR), which is developing pulmonary blood pressure drugs, and paid Pluristem $7 million in advance to develop its stem cell therapy for its own field. The deal could ultimately be worth hundreds of millions of dollars.
"They chose us, after examining the production methods of all our competitors," says Aberman. "I think that since then, the market began to take us more seriously. Our production process has value in itself, it costs a tenth of the production processes of other companies in the field." He adds, "Our proprietary production process could also generate revenue, although it won't be as material as revenue from an independent process.
Pluristem has entered a new field to use its PLX cells to rehabilitate bone marrow in blood cancer patients. Following success in preclinical trials, the cells were successfully used to treat three patients under compassionate use protocols, without a clinical trial.
Not every public company announces compassionate use treatments. Why did you do so?
Yanai: "This is our approach toward the capital market. We chose to be transparent, and I think that investors like that."
Aberman: "What would have happened if we hadn’t made an announcement, and the story leaked?"
You recently announced the selection of a distributor for your stem cells to clinical trials centers. Some people were astonished by the announcement.
Aberman: "There's a logic to all of our announcements. We dispelled foreign concerns about all our stem cells being produced at one site."
A seven year-old girl who received a compassionate treatment died recently. If she were part of a clinical trial would this still have been considered a success?
"Immediately following the treatment, we measured whether her bone marrow had rejuvenated, and the answer was unequivocally positive. Studies by other companies in similar fields also measure how many patients survive 100 days after the treatment. This patient survived 180 days, which is an eternity for these patients."
Published by Globes [online], Israel business news - www.globes-online.com - on October 9, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.